Loading...
Printed on 6/29/2026
For informational purposes only. This is not medical advice.
The Beck Depression Inventory-II (BDI-II) is a 21-item self-report measure of depression severity in adults and adolescents aged 13+. Each item is scored 0–3, giving a total of 0–63. It was developed by Aaron Beck in 1996 as a revision of the original BDI to align with DSM-IV criteria. The BDI-II is one of the most cited depression instruments in psychiatric research. Severity bands: 0–13 minimal, 14–19 mild, 20–28 moderate, 29–63 severe. Note: the BDI-II is a copyrighted instrument — this tool interprets the total score only.
Formula: Sum of 21 items (each 0–3). Total: 0–63. Minimal ≤13, Mild 14–19, Moderate 20–28, Severe 29–63.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
The BDI-II is a self-administered questionnaire consisting of 21 groups of statements. For each item, the patient selects the one statement out of four that best describes how they have been feeling over the past two weeks, including today. The four statements in each item are ordered by increasing symptom severity and scored 0 (absent or minimal), 1 (mild), 2 (moderate), or 3 (severe). Items cover a comprehensive range of depressive symptoms including sadness, pessimism, sense of past failure, loss of pleasure, guilty feelings, feelings of punishment, self-dislike, self-criticalness, suicidal ideation, crying, agitation, loss of interest, indecisiveness, feelings of worthlessness, loss of energy, sleep changes, irritability, appetite changes, concentration difficulties, fatigue, and loss of interest in sex. Patients should be instructed to answer based on the past two weeks rather than just how they feel today.
After the patient completes the questionnaire, the clinician or a trained staff member sums the raw scores from all 21 items to produce a total score. The maximum possible total is 63 (all items scored at the highest severity of 3) and the minimum is 0 (all items scored as absent). Some items allow the patient to select more than one statement — in these cases, the highest circled score for that item is used in the total. Accurate summation is straightforward but important; clinicians may wish to review the completed form item-by-item before summing to check for unanswered items, which should prompt the patient to respond before scoring. Particular attention should always be given to item 9 (suicidal ideation) at this stage, regardless of the running total.
The total score is interpreted against four severity bands: 0 to 13 indicates minimal depression, 14 to 19 indicates mild depression, 20 to 28 indicates moderate depression, and 29 to 63 indicates severe depression. These cutoffs apply to both clinical and research contexts and have been validated across diverse populations. Beyond the total score, item 9 (suicidal thoughts or wishes) must always be individually reviewed regardless of the total. A patient scoring 0 to 13 overall but endorsing item 9 with a score of 1 (wishing they were dead) or higher requires immediate individual clinical assessment of suicide risk. A change of 5 or more points from a previous administration is generally considered clinically meaningful. The BDI-II assesses the past two weeks — this timeframe should be clarified with the patient to ensure accurate responses.
Clinical researchers, academic psychiatry investigators, pharmaceutical trial teams
The BDI-II is one of the most widely used depression measurement instruments in psychiatric research, with a citation count in the tens of thousands. Its 21-item, 0 to 3 per item structure provides a continuous scale with fine-grained resolution (0 to 63) that is more sensitive to change than shorter instruments like the [PHQ-9](/tools/phq9) (0 to 27). This makes it particularly valuable as a primary or secondary endpoint in antidepressant drug trials, psychotherapy efficacy studies, and longitudinal depression cohort studies. The BDI-II's established psychometric properties — including high internal consistency (Cronbach's alpha typically 0.89 to 0.92) and extensive test-retest reliability data — support its use as a gold standard comparator when validating new depression measures.
Cognitive behavioral therapists, clinical psychologists, psychiatrists providing CBT
The BDI-II is uniquely well integrated into CBT protocols because Aaron Beck, who developed both CBT and the BDI-II, designed the instrument to measure the cognitive and affective symptoms most targeted by CBT. Many CBT therapists administer the BDI-II as brief session homework between appointments, asking patients to complete it the evening before a session so that the most recent week's mood can be reviewed at the start of the visit. Score trajectories across sessions provide objective feedback on treatment progress that complements subjective patient report. A consistent decline in scores across sessions demonstrates treatment response, while plateauing scores may signal the need to modify therapeutic techniques or address treatment barriers. The 5-point clinically significant change threshold is particularly useful for tracking week-to-week progress.
Psychiatrists, psychiatric nurse practitioners, clinical social workers
At initial psychiatric intake, the BDI-II provides an objective, standardized, and quantified measure of depression severity that supplements the clinical interview. A total score helps clinicians classify severity as minimal, mild, moderate, or severe, which in turn informs treatment planning — including whether outpatient psychotherapy alone is appropriate, whether pharmacotherapy should be initiated, or whether the severity of symptoms warrants a higher level of care. The BDI-II also identifies specific symptom areas that may not be fully explored in a brief clinical interview: item-level review can reveal prominent cognitive distortions, significant anhedonia, sleep disturbance, or hopelessness that should be prioritized in treatment. Documenting the BDI-II score at intake creates a quantified baseline for measuring subsequent treatment response.
Psychiatrists, primary care physicians prescribing antidepressants, pharmacists in collaborative care
The BDI-II is well suited for tracking depression severity at regular intervals during antidepressant treatment to assess whether the medication is producing a clinically meaningful response. Administering the BDI-II at baseline and at 4, 8, and 12 weeks after medication initiation allows clinicians to quantify the magnitude of improvement. A 50% reduction in total score from baseline is widely used in research as the definition of treatment response, and a score of 12 or below is often considered remission. In clinical practice, a score that remains above 20 after 8 weeks at a therapeutic antidepressant dose should trigger consideration of dose adjustment, augmentation, or switching. The finer scale resolution of the BDI-II compared to the [PHQ-9](/tools/phq9) allows detection of smaller but clinically meaningful changes in severity.
Endocrinologists, cardiologists, oncologists, chronic disease nurses, liaison psychiatrists
Depression is a highly prevalent comorbidity in patients with chronic medical illness, including type 2 diabetes, coronary artery disease, heart failure, cancer, and chronic pain conditions. The BDI-II has been validated for use in multiple chronic illness populations and provides a thorough assessment of both the cognitive-affective and somatic symptom domains of depression. One important consideration in medically ill patients is that somatic items on the BDI-II (fatigue, sleep disturbance, appetite changes) may be elevated due to the medical illness itself rather than depression. Clinicians should review somatic items in context and give additional weight to cognitive and affective items (sadness, hopelessness, worthlessness, anhedonia) when interpreting scores in this population. A referral to the [GAD-7](/tools/gad7) for anxiety comorbidity is also recommended, as depression and anxiety frequently co-occur in chronic illness.
Item 9 of the BDI-II directly assesses suicidal ideation, ranging from 0 (no suicidal ideation) to 1 (wishing they were dead) to 2 (wanting to kill themselves) to 3 (would kill themselves if they had the chance). A patient can score 0 to 13 overall (minimal depression) and still endorse item 9, which requires immediate individual clinical assessment of suicide risk. Never allow a low total score to substitute for item-level review of suicidal ideation. If item 9 is endorsed at a score of 1 or higher, directly ask the patient about passive death wishes versus active suicidal ideation, plan, intent, and access to means before concluding the session. Document the item 9 response and your clinical assessment in the medical record.
The choice between the BDI-II and the [PHQ-9](/tools/phq9) depends on the clinical or research context. The BDI-II's 21-item structure, 0 to 63 scoring range, and extensive psychometric validation make it more sensitive to subtle changes in depression severity and better suited as a research endpoint. The [PHQ-9](/tools/phq9) requires only 2 to 3 minutes to complete (versus 5 to 10 for the BDI-II), is freely available without copyright restrictions, and is better integrated into primary care workflows and EHR systems. For a busy primary care practice doing population-level depression screening, the [PHQ-9](/tools/phq9) is more practical. For a psychiatric research study or a CBT practice needing granular weekly tracking, the BDI-II provides superior measurement precision.
In both clinical and research contexts, a change of 5 or more points on the BDI-II total score from a previous assessment is generally considered the minimum clinically significant difference — meaning it reflects a real change in depression severity rather than measurement noise. When monitoring treatment response, tracking absolute score changes rather than just band transitions is important: a patient who drops from 30 to 25 (severe to moderate) has improved meaningfully even though they remain in the moderate range. Conversely, a change of 1 to 3 points between sessions may reflect normal test-retest variability rather than true improvement. The 5-point threshold is most reliable over intervals of 4 weeks or more, as shorter intervals show greater measurement variability.
Several BDI-II items assess symptoms that overlap with manifestations of medical illness: fatigue (item 20), sleep changes (item 16), appetite changes (item 18), and loss of energy (item 15). In patients with cancer, heart failure, diabetes, chronic kidney disease, or chronic pain, these items may score 2 to 3 due to the medical illness alone rather than depression, inflating the total score. When interpreting BDI-II scores in medically ill patients, give additional clinical weight to purely cognitive and affective items (sadness, hopelessness, pessimism, anhedonia, worthlessness, guilt, self-dislike) and consider whether the overall score reflects true depressive psychopathology or medical symptom burden. Some research protocols use a cognitive subscale of the BDI-II that excludes somatic items for medically ill populations.
A BDI-II score of 29 or above falls in the severe depression range and indicates that the patient is experiencing significant depressive psychopathology that warrants prompt clinical evaluation and likely active treatment. If a patient completes the BDI-II in a non-clinical setting (for example, as part of an online symptom checker or research intake) and scores in the severe range, they should be directed to seek evaluation by a mental health clinician without delay. In clinical settings, a score above 28 on intake or during treatment should trigger same-day review by the treating clinician, assessment of suicide risk (with particular attention to item 9), and consideration of whether the current treatment plan is adequate.
One practical advantage of the BDI-II in CBT settings is that it can be assigned as brief session homework — completed the evening before or the morning of each appointment — to provide a continuously updated severity measure that the therapist and patient review together at session start. This weekly tracking reveals patterns that are clinically useful: weeks when scores spike may correspond to identified stressors or cognitive distortion flare-ups, while steadily declining scores provide objective reinforcement of treatment progress for patients who may discount their own improvement. The BDI-II session-homework approach has strong empirical support in CBT outcome research and is explicitly recommended in many CBT treatment manuals. The [PHQ-9](/tools/phq9) can be used as a quicker alternative if session time is limited.
The BDI-II instructions specify that patients should rate each item based on how they have felt over the past two weeks, including today. This timeframe is often not emphasized enough when administering the questionnaire, and patients sometimes respond based on how they feel at the specific moment of administration (state) rather than their average experience over two weeks (trait). If a patient appears to be answering based on their current moment rather than the past two weeks, gently redirect them: 'Please think about how you have generally been feeling over the past 14 days, not just right now.' This is particularly important in patients with highly variable mood, as they may over- or underestimate their typical symptom burden depending on their mood at the time of completion.
Your BDI-II score reflects the overall severity of depressive symptoms over the past two weeks. A score of 0 to 13 indicates minimal depression, meaning you are experiencing few or no clinically significant depressive symptoms. A score of 14 to 19 suggests mild depression, with some symptoms present that may benefit from monitoring or early intervention. A score of 20 to 28 indicates moderate depression, where symptoms are likely affecting your daily functioning, work performance, and interpersonal relationships. A score of 29 to 63 indicates severe depression, warranting prompt clinical evaluation and likely active treatment.
Regardless of the total score, item 9 (suicidal thoughts or wishes) should always be individually reviewed. Any endorsement of suicidal ideation on this item requires immediate clinical attention, even if the overall score falls in the minimal or mild range. A change of 5 or more points from a previous assessment is generally considered clinically meaningful.
The BDI-II is appropriate for assessing depression severity in adults and adolescents aged 13 and older. It is one of the most widely used instruments in psychiatric and psychological research and is commonly employed in clinical settings to quantify depression severity at intake, track treatment response over time, and support treatment planning decisions.
The BDI-II is particularly well suited for research contexts where fine-grained measurement of depression severity is needed, as its 21-item format and 0 to 3 scoring per item provide greater resolution than shorter screening tools like the PHQ-9. It is also used in cognitive behavioral therapy protocols to monitor session-to-session progress.
The BDI-II is a self-report measure and shares the limitations inherent in all such instruments: it depends on the respondent's willingness and ability to accurately report symptoms. Patients with poor insight, psychotic features, or severe cognitive impairment may not provide reliable responses. It should not be used as the sole basis for a depression diagnosis.
The BDI-II emphasizes cognitive and affective symptoms of depression and may be less sensitive to somatic or atypical presentations. In medically ill patients, somatic items (sleep changes, fatigue, appetite changes) may inflate scores due to the underlying medical condition rather than depression per se.
The BDI-II is a copyrighted instrument published by Pearson, requiring purchase of forms for clinical use. This limits its accessibility compared to freely available tools like the PHQ-9 or MDI. Additionally, standard cutoff scores were developed primarily in Western populations, and cultural factors may influence response patterns.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Free PHQ-9 depression screening questionnaire. Take the Patient Health Questionnaire-9 to assess depression severity with instant scoring and interpretation. Also screen for anxiety with [GAD-7](/tools/gad7).
OpenMental HealthScreen for depression using the WHO-endorsed Major Depression Inventory (MDI). A 10-item self-report questionnaire scoring 0–50.
OpenMental HealthFree GAD-7 anxiety screening questionnaire. Take the Generalized Anxiety Disorder 7-item scale to assess anxiety severity with instant scoring and interpretation. Also screen for depression with [PHQ-9](/tools/phq9).
OpenFitnessEstimate ideal bedtimes or wake times based on 90-minute sleep cycles and sleep latency. Helps plan schedules around 7-9 hours of sleep. Poor sleep affects calorie balance — track with [TDEE Calculator](/tools/tdee-calculator).
OpenEnter the total BDI-II score (sum of 21 items, each 0–3). The BDI-II is a copyrighted instrument — this tool interprets the total score only.